# Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer

> **NCT05447715** · PHASE2 · UNKNOWN · sponsor: **Weijian Guo** · enrollment: 134 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Fruquintinib

## Key facts

- **NCT ID:** NCT05447715
- **Lead sponsor:** Weijian Guo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-31
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-01-31
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2022-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05447715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05447715, "Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05447715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*